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(57) ABSTRACT 
A bioconjugate including a nanoparticle covalently linked to 
a biological vector molecule. The nanoparticle is a generally 
radioactive metal ion and most typically a metal sulfide or 
metal oxide. The biological vector molecule is typically a 
monoclonal antibody or fragment of a monoclonal antibody 
or a peptide having a known affinity to cancer cells. One or 
more additional, different biological moieties may be 
covalently linked to the nanoparticle in addition to the 
biological vector molecule to enhance its activity. The 
bioconjugate of the present invention has utility as an 
effective radiopharmaceutical to deliver a radiolabel in 
tumor treatment. 
11 Claims, 3 Drawing Sheets 
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BIOCONJUGATES OF NANOPARTICLES AS 
RADIO PHARMACEUTICALS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This invention claims benefit of copending United States 
Provisional Application Ser. No. 60/208,631 filed Jun. 1, 
2000. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
2 
alized in one of the side chains by -C6H 4-NCS or other 
groups to form a covalent bond with proteins. 
Entrapment of metal ion into a framework of muldiden-
tate poly (amino carboxylates) such as DOTA, DTPA 
5 covalently attached to mAbs has been proven to provide 
thermodynamically stable compounds suitable for clinical 
trials. Nevertheless, results obtained for human patients and 
for animal models indicate that the applicability of these 
compounds is limited by the high level of radioactivity in 
10 blood, bone marrow, kidney and liver. This necessitates 
reduction of in-vivo decomplexation of metal ions and 
strengthening radiolabel-mAb bond. 
The development of the subject matter of this application 
was partially supported by a grant from the National Science 
Foundation (NSF-EDS-9876265). Accordingly, the U.S. 15 
government may have rights in this invention. 
The tumor uptake and overall biodistribution of the radio-
labeled compound depends on the metabolism of the mAb 
and the strength of radionuclide-antibody link. Although 
there is a substantial room for improving targeting properties 
of mAbs, all studies indicate that the thermodynamic and 
kinetic stability of the chelate in vivo of is of primary 
importance for the design of clinically successful radio-
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates generally to the effective diagnosis 
and treatment of cancer patients and, more specifically, to 
radiopharmaceuticals for use in connection with radioim-
munotherapy and radioimmunodection. 
2. Background 
Effective treatment of cancer patients by using radioim-
munotherapy (RAIT) and diagnostics of malignant tumors 
20 chemicals. 
25 
The equilibrium constant of chelation for the best chelates 
used in RAIT and RAID is comparable to that for some 
proteins present in blood. Therefore, chelates are inherently 
prone to slow exchange of radioactivity with tumor-
indifferent proteins. When radiopharmaceuticals are admin-
istered intravenously, they encounter endogenous metal-
by radioimmunodetection (RAID) requires drastic improve-
ment of tumor-to-background (T/B) distribution of a radio-
label. T /B ratio is the principal parameter that determines 30 
tumoricidal action, sensitivity of tumor detection and, most 
importantly, systemic toxicity of the compound. Radioactive 
isotopes of metals are used very often in various modalities 
binding proteins such as albumin in concentrations 
100-1000-fold greater than that of the radiopharmaceutical. 
Loss of radiometal to serum proteins leads to accumulation 
of radioactivity in normal tissues, especially liver, spleen, 
and kidney, reducing the radioactivity available for tumor 
uptake. Stability of the radioimmunoconjugate is a critically 
important factor in determining its usefulness for in vivo of RAIT and RAID in the form of conjugates with mono-
clonal antibodies (mAbs). 
Attachment of the radioisotope to the targeting molecule 
is the most important part of the preparation of the radio-
conjugate. In some cases, a direct approach to radiolabeling 
of antibodies with therapeutic radionuclides can be adopted 
by reducing internal disulfide bonds within the antibody and 
allowing, for example, technetium or rhenium ions to react 
directly with the resultant sulfhydryl groups. However, 
labeling strategies usually rely on the utilization of a mul-
tidentate ligand capable of selective chelation of the desired 
radionuclide. In order to avoid the release of the metal ion 
in the circulation and inevitable radiation injuries to healthy 
organs, metal ions must be strongly complexed by a chelat-
ing agent. 
Ideally, the chelated nuclide would be rapidly excreted via 
the urinary tract without intracellular retention, with intact 
conjugate accumulating and being retained selectively at the 
tumor site. This is however clearly not always the case, and 
in several instances, persistent and unwanted retention of 
metallic nuclides has been reported. As the in vivo behavior 
of a given nuclide-chelator complex cannot be predicted 
easily, the choice of potential multidentate ligands is guided 
by conventional chelation chemistry. Macrocyclic multiden-
tate ligands which provide the highest thermodynamic sta-
bility of the complex are frequently used for preparation of 
immunoconjugates. The typical examples of chelating 
agents are diethylenetriaminepentaacetic anhydride (DTPA), 
(diethylenetriaminetetraacetic acid (DTTA), 
(1,4, 7 ,10-tetraazacyclododecane-N ,N=,N =a>, 
N =a>=-tetraacetic acid) (DOTA), ethylenediaminetetra 
(methylene phosphonate) (EDTMP), 1,1-hydroxyethylidine 
diphosphonate(HEDP) and derivatives thereof. For prepa-
ration of conjugated structures they are frequently function-
35 
applications. This fact was experimentally established for 
the majority of radionuclides. 
For complexes of 111In and bleomycin, partial dissocia-
tion of the ion from bleomycin caused severe bone marrow 
toxicity and increased the background y-radiation signifi-
40 cantly impairing its therapeutic and imaging capabilities. 
The tumor-to-background ratio varied from 1.0 to 2.9. Even 
for one of the most widely used and the strongest 111In 
chelate with octadentate ligand DTPA (Kaiss=28.5) a high 
liver background has been observed. Most researchers agree 
45 that chelate instability is the primary reason for various 
immune mechanisms which contribute to accumulation of 
the radioactivity in non target organs. Recent study clearly 
indicate the direct dependence between the thermodynamic 
stability of various chelates (NTA, EGTA, EDTA, DTPA) 
50 bound to the B72.3 antibody and the tissue distribution and 
accumulated activity in blood and kidney. 
Retention of 111In in normal tissues has been the major 
limitation in RAID applications. Improved clearance of 
111 In from liver tissue correlated with the strength of a labile 
55 linkage between the antibody and the chelator and with the 
structure of the chelator to provide for higher stability under 
in vivo conditions. 
The loss of metal ion in circulation greatly limits the 
utilization of potent radionuclides with convenient energy 
60 and half-life characteristics such as 212Pb. The short decay 
of 212Pb time (10.6 hours, ~, 0.57 and 0.33 MeV) permits 
rapid clearance from the system. When conjugated to spe-
cific mAb 103 A, 212Pb-DOTA chelate was very efficacious 
at eliminating the tumor even in mice with large tumor 
65 burdens. However, due to lower pH values found in cells in 
which catabolism occurs, 212Pb escapes the chelator and is 
taken up in bone and marrow. Bone marrow toxicity in this 
US 6,689,338 B2 
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case was so high that accumulation of 212Pb in bones was 
dose limiting and lethal. Loss of the specificity of radio metal 
deposition was observed for 46Sc, 67 Ga, and 90Y when the 
ion was not strongly chelated to its ligand. 
Incorporation of a radiometal label into the protein struc- 5 
ture by using nitrogen and sulfur atoms of aminoacids (NS 
systems) is very popular for technetium and rhenium. Com-
parative stability of these chelates is quite high. Importantly, 
metal species can be incorporated in an anionic form that 
makes recomplexation by native proteins less probable. 10 
Nevertheless, 188Re-labeled mAbs were found to be a mar-
ginal agent for controlling tumor growth. The failure of 
188Re-IgG in some tumor models may be related to the 
combination of apparent instability of the labeled product 
and its short physical half-life. Interestingly the dissociation 15 
of 188Re from the protein occurred more quickly that for 
other isotopes such as 88Y. The release of rhenium is likely 
to be assisted by reoxydation of the chelate to ReO 4 - by 
dissolved oxygen. 
Importantly, for yttrium (90Y, 88Y), lead (212Pb) and 20 
samarium (153Sm) the strength of the chelates must be 
particularly high. In ionic form these metals are capable of 
replacing Ca2 + ions from bone, which halts excretion of the 
radionuclide and causes augmented radiation damage to 
25 healthy tissues. 
4 
SUMMARY OF THE INVENTION 
In accordance with the present invention metal chelates 
are replaced with small (2-5 nm in diameter) clusters of 
metal sulfide nanoparticles bound to mAbs or other biologi-
cal molecules via a bifunctional organic stabilizer. The core 
materials of the nanoparticles, i.e. transition metal sulfides, 
are virtually insoluble in aqueous solutions due to partially 
covalent character of the crystal lattice. Negligible concen-
tration of ionic species prevents transchelation in serum and 
release of radioisotopes in circulation. 
Nanoparticles (NPs) combine properties of bulk solids 
and relatively large molecules. The core of NPs is made of 
inorganic material and retains some physical and chemical 
properties of its bulk predecessor, while the solubility and 
chemical reactivity is determined by a thin, virtually mono-
molecular layer, of organic molecules adsorbed to NP. This 
layer passivates the surface of the solid and protects the NP 
from further growth. A chemical compound forming this 
layer is often referred to as a stabilizer. The inorganic core 
may contain 100 to 10,000 atoms depending on its diameter 
(1-10 nm). The size can be accurately assessed by the 
position of UV absorption peak that was shown to shift to 
shorter wavelengths for smaller NPs due to size-quantization 
effect. Very small size, uniformity of particles, and critical 
role of the surface distinguishes NPs from both colloidal and 
molecular systems. 
Although a large variety of materials can be prepared in 
this form, predominantly metal sulfides and oxides have 
been studied for preparation of NPs. Organic thiols, R-SH 
are known to be excellent stabilizers for these materials due 
to formation of a relatively strong covalent R-S-M link, 
where M stands for metal atom on the surface of nanopar-
ticle. Numerous methods have been proposed for prepara-
tion of NPs in solid and liquid media, as well as at interfaces. 
See, Fendler, J. H. Membrane-mimetic Approach to 
Advanced Materials. Advances in Polymer Science. Vol. 
113. Springer-Verlag: Berlin, 1994; C. Luagdilok and D. 
Meisel, Size Control and Surface Modification of Colloidal 
The nature of medical applications imposes multiple 
requirements on the chemical characteristics of a potential 
chelating ligand. It has to be (a) strong (multidentate) 
complexing agent for the metal ion, (b) hydrophilic to afford 
30 
solubility in water, ( c) nontoxic, ( d) capable of incorporating 
into a protein structure without causing its denaturation. For 
virtually every single radionuclide one has to design a 
special chelating system. For example macrocyclic bifunc-
tional chelating agents, in particular, DOTA, derivatives 
35 
incorporating yttrium-90 and indium-111 have shown excel-
lent kinetic stability under physiological conditions. 
However, the slow formation of yttrium-DOTA complexes 
presents a technical problem that can lead to low radiola-
beling yields unless conditions are carefully controlled. 
40 Semiconductor Particles, Is. J. Chem, 1993, 33, 53; P. V. 
The most successful chelating agents for preparation of 
radioconjugates are the products of a complex organic 
synthesis. Quite representative examples of a synthetic pro-
cedure can be found in Brechbiel, M. W.; Gansow, 0. A; 
Atcher, R. W.; Schlom, J.; Esteban, J.; Simpson, D. E.; 45 
Colcher, D., Synthesis of 1-(P-isothiocyanatobenzyl) 
Derivatives of DTPA and EDTA. Antibody Labeling and 
Tumor Imaging Studies, Inorg. Chem., 1986, 25, 
2772-2781. They consist of more than 6 consecutive steps. 
Synthetic sophistication not only increases the cost of the 50 
drug but also compromises the quality of the pharmaceutical 
by restricting how the label can be attached to mAb. Direct 
binding used for 99mTc and 186Re without specilly designed 
chelating agents simplifies the procedure. However, it can-
not be applied for other metals and may induce conforma- 55 
tional changes in mAb or its fragments. 
Entrapment of a metal ion into a framework of multiden-
tate complex yields a thermodynamically stable structure, 
but quite often, is slow to form. Typically, incorporation of 
a radioactive ion takes >3 hours. The fast forming chelates 60 
like those of EDTA, undergo rapid transchelation to blood 
proteins. Slow kinetics of metal incorporation decreases the 
overall activity of short half-life radionuclides and necessi-
tates removal of unbound radioactive species. 
It is thus an object of the present invention to provide a 65 
new method of preparation of radioimmunoconjugates to 
obtain more stable agents for radiotherapy and diagnostics. 
Kamat, Interfacial Charge Transfer Processes in Colloidal 
Semiconductor Systems, Prag. Reaction Kinetics, 1994, 19, 
277. By choosing an appropriate stabilizer and reaction 
conditions one can alter the diameter of the core with a 
precision of a few Angstroms. 
Unique properties of NPs, i.e. their intermediate position 
between single molecule and a bulk compound, have made 
them excellent candidates for various applications. So far, 
scientists viewed them as perspective candidates for optical 
and electronic devices, while medical applications of inor-
ganic nanoparticles are very limited. 
The term nanoparticle appears in medical literature quite 
often. In most cases it is used to describe objects of from 30 
to 300 nm in diameter represented by vesicles, polymers or 
colloids. These species are used for drug delivery and for 
diagnostic purposes. Confusion of terms used in different 
fields of chemistry should not obscure the fundamental 
difference that drug delivery agents are expected to remain 
in the blood stream for relatively long time while the 
radioimmunoconjugates must have a rapid blood clearance 
which is hardly achievable with large species 50-300 nm in 
diameter. Accordingly, it is contemplated that the term 
nanoparticles in the present invention includes particles of a 
smaller diameter. 
The use of inorganic clusters in the nanometer region has 
been limited so far to conjugates of Fe3 0 4 magnetic clusters 
proposed for MRJ contrast agents. Ideologically, these are 
US 6,689,338 B2 
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the assemblies that are quite similar to MPC: a mAb or other 
targeting compound attached to the magnetic core causes 
magnetic material to accumulate in tumor tissue, which 
increases the contrast of MRI images. Magnetic conjugates 
were proven to be quite efficient agents for MRI. From 5 
chemical point of view, synthetic approaches must be 
entirely different because of difficulty of covalent modifi-
cation of oxide surfaces used in magnetic imaging. Fe2 O3 
and Fe 3 O 4 nanoparticles and coating material 
(polyelectrolytes) are held together mostly by electrostatic 10 
forces. Metal sulfides offer a possibility to form stronger and 
more precisely organized assemblies via covalent bonds. 
Importantly, the requirements to chemical stability in radio-
immunoconjugates is substantially stricter than in magnetic 
imaging because of the high toxicity of radioactive materi- 15 
als. 
6 
molecules. This will increase the uptake of the labeled 
compound by the cancerous cells and will promote a 
more uniform distribution of the drug within the tumor 
tissue. Conjugates of this type are currently unavailable 
by chelate labeling technique owing to complexity of 
the procedure and relatively short life-time of radionu-
clides. 
Accordingly, application of nanoparticle/protein conju-
gates should significantly improve the detection limit of 
cancer, increase effectiveness of radiotherapy and reduce the 
overall radiation toxicity. Practical benefits of introducing 
nanoparticles in nuclear medicine also include the possibil-
ity of using low activity isotope sources. Since each nano-
particle contains 100-10,000 metal atoms, high radioisotope 
enrichment of the original stock solution is not required. 
A better understanding of the present invention, its several 
aspects, and its objects and advantages will become apparent 
to those skilled in the art from the following detailed 
description, taken in conjunction with the attached drawings, 
Here and later, the term "solution" shall be used rather 
than "dispersion" to describe nanoparticles in liquid media 
in order to emphasize the similarity with true molecular 
solutions. For nanoclusters 1-10 nm in diameter it is not 
only a valid but also a more appropriate terminology in 
accord with their chemical properties quite different from 
the common colloidal dispersions. 
20 wherein there is shown and described the preferred embodi-
ment of the invention, simply by way of illustration of the 
best mode contemplated for carrying out the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic of a nanoparticle surrounded by a 
stabilizer with a functional terminal group. 
FIG. 2 is a schematic example of a conjugation reaction 
between functionalized nanoparticles and a protein. 
In connection with the present invention, instead of a 
multidentate ligand with a radioactive ion in the middle a 25 
radioactive nanoparticle is covalently linked to a biological 
vector molecule such as mAb, its fragment, peptide, or 
others. NPs are synthesized separately from a suitable iso-
tope and then conjugated to biological molecules by using 
procedures similar to those for chelates. For example, ter-
minal groups of stabilizer molecules coating NPs can be 
chemically modified to p-isothiocyanotobenzyl derivatives, 
which can be coupled to NH2 groups of lysine residues of 
proteins. Alternatively, NP-protein conjugates can be pre-
pared via NP-biotin dyads (NP-B) to provide a synthetic 35 
route to preparation of heterogeneous conjugates combining 
two different bioactive moity. The new radiopharmaceuti-
cals substantially improve the clinical properties of currently 
used radiolabeled compounds for the following reasons: 
30 
FIG. 3 is a schematic illustrating the preparation of 
biotine-modified nanoparticles. 
(1) The dissociation constants, K, for chelates are many 
40 
orders higher than that of metal sulfides of clinical 
interest: logK for the strongest chelates is known to be 
>-30, while logK(In2 S3)=-73.24, logK(CuS)=-35.2, 
logK(Bi2S3)=-97, logK(Ag2S)=-49.7. When a radio- 45 
active metal is present in the body in the form of 
virtually insoluble largely covalent sulfide cluster, the 
formation of metal ions leading to transchelation by 
natural proteins is practically eliminated. Thus, the 
biodistribution of a radioactive material will not be 
50 
compromised by the loss of chelated ion while in 
circulation. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT 
Before explaining the present invention in detail, 1t 1s 
important to understand that the invention is not limited in 
its application to the details of the construction illustrated 
and the steps described herein. The invention is capable of 
other embodiments and of being practiced or carried out in 
a variety of ways. It is to be understood that the phraseology 
and terminology employed herein is for the purpose of 
description and not of limitation. 
Properties of nanoparticles of metals were first predicted 
by theoretical work by L. Brus on the basis of quantum 
mechanical calculations. See Brus, L., Radiationless Tran-
sitions in Cdse Quantum Crystallites, Is. J. Chem., 1993, 33, 
15 and references therein (incorporated by reference). It was 
found that the absorption spectra of semiconductor particles 
with the size of 1-10 nm is supposed to strongly depend on 
their diameter. Experimentally they were first observed by 
A Heinglein and M. Gratzel, who confirmed the predictions. 
See A Henglein, Small-particle Research: Physicochemical 
Properties of Extremely Small Colloidal Metal and Semi-
conductor Particles, Chem. Rev., 1989, 89, 1861. and B. 
(2) Numerous stabilizer molecules coating nanoparticles 
permit for several identical covalent bridges to be 
formed in one conjugation step making the overall 
stability of the conjugate substantially higher. 
(3) Replacement of a metal complex with nanoparticles, 
which can be prepared for 10-20 min, eliminates long 
and expensive multistep procedure of chelate synthesis. 
Since inorganic core is much more tolerant to experi-
mental conditions than elaborate organic molecules, 
surface activation and modification, should it be 
necessary, can be carried out as a one-pot synthesis 
without involvement of protective groups. 
55 O'Regan and M. Gratzel, a Low Cost, High Efficiency Solar 
Cell Based on Dye-sensitized Colloidal TiO2 Films, Nature, 
1991, 353, 737 and references therein (both incorporated by 
reference). After that optical and electronic properties of 
semiconductor nanoparticles and particularly metal sulfides 
( 4) Availability of multiple attachment points on the 
surface of nanoparticles enables design and preparation 
of radioimmunoconjugates with multiple targeting 
60 were in the focus of many scientists. 
Typically, NPs are synthesized by arrested precipitation in 
the presence of thiols. For all thiols, -SH end forms a 
strong bond with surface atoms of a metal while the opposite 
end the stabilizer can carry various functional groups suit-
65 able for further derivatization. The NPs obtained following 
this general recipe can be represented by an approximate 
model in FIG. 1. 
US 6,689,338 B2 
7 
One aspect of the present invention involves the synthesis 
8 
moles) are injected in vigorously stirred solution. Initially 
transparent colorless mixture becomes intensively brown, 
which indicates formation of nanoparticles. Nanoparticles 
can be separated from the liquid phase by adding 1:1 volume 
of nanoparticles easily redispersible in water. The later 
requirement is necessary for future conjugation to proteins 
which do not tolerate hydrophobic media. In connection 
with the present invention there is provided a relatively 
uniform method for the synthesis of ReS2 , Ag2 S and In2 S3 
nanoparticles. 
5 of acetone. After centrifugation, the dark solid washed with 
ethanol and dried. For further modifications ReS2 nanopar-
ticles can be redispersed in water, DMF, DMSO and other 
polar solvents. When a radioconjugate is administered for the purpose of 
cancer therapy, the portion of gamma-quanta in gamma-
emitting nuclides should be minimized to avoid unnecessary 10 
whole body irradiation. Among many other perspective 
radionuclides 111 Ag and 186Re have the lowest abundance of 
gamma-radiation: 7% and 16% respectively [Schubiger, A 
P. et al. Bioconjugate Chem., 1996, 7 (2), 165-179]. 
Unfortunately, low chemical stability of corresponding che- 15 
lates causes serious practical problems for both metals. 
Silver nuclides are particularly exemplary in this respect. 
Despite favorable emission properties, 111 Ag has not been 
viewed favorably in nuclear medicine because of high 
lability of the metal center. Stability constants rarely exceed 20 
1000, and the highest constant described for an 
18-membered N2S4 system was 1014 [Craig, AS. et al. J. 
Chem. Soc., Perkin Trans., 1990, 2, 1523-1531]. It has to be 
considered in the latter case that this is an absolute and not 
a conditional constant. This means that the amines in the 25 
multidentate chelate will be protonated in physiological 
solution, with the conditional constants being therefore 
much lower. The stability constant for silver sulfide is 5· 1049 
and Ag2S nanoparticles are virtually indestructible under 
physiological conditions. By using the nanoparticle technol- 30 
ogy the preparation of radioimmunoconjugates with 111 Ag 
becomes possible. 
Chelates of indium are considered to be one of the most 
promising and are currently undergoing clinical trials for 
radioscintillation imaging of cancer. Indium is also preferred 35 
for the present invention because In2S3 nanoparticles should 
substantially improve the performance of 111In pharmaceu-
ticals. The transchelation reactions will be eliminated and 
therefore the tumor-to-background ratio will be improved 
(stability constant of In2S3 is l.7·10
73
). The preparation of 40 
the conjugates will be simplified and will become more cost 
effective. Besides that, imaging capabilities of 111 In suffer 
from its rather short half-live, t112=67 hours. Quite often the 
radioscintillation study has to be conducted for a few days 
after initial injection in order to detect metastases. Although 45 
t112 cannot be changed, but the actual contrast of the image 
will be substantially improved for NP conjugates as com-
pared to chelates particularly for period of time longer than 
t112 has passed due to the greater number of 
111 In nuclei per 
conjugate retaining their activity. Improvement of targeting 50 
and blood clearance times can also be achieved via attach-
ment of several tumor-seeking biological molecules to one 
radiolabel, which is quite complicated synthetically for 
111In-chelates. NPs of silver, indium, rhenium, copper and 
other sulfides can be synthesized by arrested precipitation in 55 
the presence of thiols. For all thiols, -SH end forms a 
strong bond with surface atoms of a metal while the opposite 
end the stabilizer can carry various functional groups suit-
able for further derivatization. Synthesis of NPs is preferably 
accomplished as exemplified here for rhenium sulfide nano- 60 
particles and indium sulfide nanoparticles. 
EXAMPLE 1 
EXAMPLE 2 
50 mg of InCl3 and 0.18 ml of thioglycerol, TG, (or 32 mg 
of l-amino-2-methyl-2-propanethiol hydrochloride, AMPT) 
are dissolved in 20 ml of deoxygenated water (N2 , bubbling 
for 20 minutes). The molar concentration of stabilizer is ten 
times that of the metal. This mixture is vigorously stirred and 
3.39 ml of 0.lM aqueous solution of sodium sulfide was 
added. Indium sulfide nanoparticles in the solution were 
sedimented from the mother liquor by isopropanol as a white 
powder, that can be used in subsequent modification reac-
tions. 
The size of nanoparticles can be controlled by several 
means: (1) addition of a solvent with lower electron donor 
capacity (CH30H), (2) reduction the stabilizer/metal molar 
ratio; or (3) increase of the temperature of the solution 
during addition of s2-. It is preferred to work with nano-
particles of 1-3 nm in diameter, which are regularly obtained 
under ambient conditions. 
The size of the nanoparticle clusters can be readily 
assessed by transmission electron microscopy (TEM) and by 
using UV-absorption spectrophotometry. The peak in 
UV-absorption strongly depends of the particle diameter: for 
CdS the peak shifts from 250 nm to 480 nm when the 
diameter on the nanoparticles increases from 14 A to 100 A. 
Emission properties of nanoparticles change according to 
their diameter as well. However, there is a strong influence 
of the emission spectrum of nanoparticles on surface 
conditions, and, therefore, the usage of absorption charac-
teristics for size estimate is preferential. 
Referring to FIG. 1, the surface of the NP 10 is inherently 
functionalized by chemical groups 30 present in thiol sta-
bilizers. Thiolate chemistry enables using various deriva-
tives without significant alteration of the preparation proce-
dure of nanoparticles. There is a substantial variety of 
commercially available thiols with -OH, -SH, -COOH, 
and -NH2 functional groups. The stabilizers that are cur-
rently preferred for preparation of nanoparticles include 
thioglycerol (-OH), mercaptosuccinic acid (-COOH), 
thioglycolic acid (-COOH), and l-amino-2-methyl-2-
propanethiol (-NH2) (the terminal functional is group is 
indicated in parenthesis). The selection of a specific terminal 
functional group L, 20 in FIG. 1, is governed by the 
conjugation reactions planned for the nanoparticle. Should it 
be necessity to vary the stabilizer structure, for instance the 
hydrocarbon chain length, one can synthesize the compound 
series by using classical methods of organic chemistry. 
Changes occurring with the organic shell around the 
nanoparticle may be monitored using methods such as: 
fluorescence spectroscopy, UV-VIS absorption 
spectroscopy, Fourier transform infrared spectroscopy 
(FTIR), Raman spectroscopy, and nuclear magnetic reso-
nance (NMR). These methods can be use to generate mul-
tifaceted characterization of the layer of stabilizer by prob-
ing optical vibrational, and magnetic properties of a- and 50 mg ReC15 (1.38xl0-
4 moles) and 0.02 ml of thioglyc-
erol (1.38xl0-4 moles) are dissolved in 15 ml of DMF. The 
reaction mixture is purged with nitrogen to get rid of 
dissolved oxygen and 2.75 ml of 0.lM Na2S (2.75lxl0-
4 
65 it-bonds. 
Binding of the stabilizer to the NP surface significantly 
alters the proton and carbon signals in the vicinity of the 
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interface. Therefore, assignment of the signals may be made 
in the analysis of NMR data. Two-dimensional NMR 
(COSY and NOESY) can be used for determination of a 
source of the peak as well as the environment of a selected 
group. 
Relative intensity of 1 H and 13C signals in functional 
groups is the most direct method to monitor the modification 
10 
Classical reaction with thiophosgene results in the conver-
sion of NP-S-C6H 4-NH2 to NP-S-C6H 4-NCS. 
Thiophosgene is not soluble in water and is normally used 
in the form of chloroform solution. Conversely, NPs are 
5 rather hydrophilic. Nevertheless, finding a common solvent 
for these two reagents is not required since the modification 
reaction is quite efficient at the interface of CH Cl3 and a 
basic aqueous solution (pH=8.5) forming unstable emulsion of the surface of nanoparticles. The ratio of integral inten-
sities of NMR signatures of a protein and a nanoparticle 
provides the estimate of NP/protein ratio. Importantly, NMR 10 
enables evaluation of the protein conformation and, thus, its 
biological activity, which can be correlated with the data 
obtained by ELISA and immunofluorescence. 
upon stirring. The average number of -C6H 4-NCS groups 
per nanoparticles can be controlled via the overall reaction 
time and amount of thiophosgene. A mixture of two stabi-
lizers may also be used for the preparation of nanoparticles, 
for instance, HS-C6H 4-NH2 and thioglycerol terminated 
by fairly inactive -OH groups. In this case, only Infrared and Raman spectroscopy may be used to generate 
structural information to complement and augment the data 
obtained by NMR. The extent of surface modification of 
NPs may be detected by using the intensity of vibrational 
bands of -OH, -NH2 , -COOH, C=O, C-NH and other 
functional groups involved in the reaction. 
Imaging of NP-protein conjugates using transmission 
electron microscopy (TEM) may be performed after staining 
the organic part by uranium or osmium salts to increase the 
contrast. N anoparticles of the proposed metal sulfides can be 
readily found in TEM pictures without any additional pro-
cedures. TEM of the conjugates provides information about 
distribution of the NPs along the protein chain and possible 
crosslinking processes. 
Preparation of bioconjugates of NPs can be accomplished 
by using standard biochemical procedures. Aromatic 
p-isothiocyanato group has been extensively employed to 
efficiently couple chelates, fluorescence probes, boron clus-
ters or spin labels to proteins and therefore can be used for 
nanoparticles. p-Isothiocyanotobenzyl moiety targets 
-NH2 functional groups in lysin aminoacid residues (FIG. 
2 wherein 1 represents the nanoparticle and 2 represents the 
residue). Quite often they do not play a critical role in the 
biological activity of a protein and located in open parts of 
the globule. Lys and, to a lesser extent, Cys aminoacids are 
the targets for thiazolidine-2-thione and succinimidyl link-
ers. Nanoparticles terminated with hydroxyls are particu-
larly suitable for this conjugation. A cyanuric acid conden-
sation product, 4,6-dichloro-1,3,5-triazin-2-ylamino group, 
provides an alternative, more reactive and more hydrophilic 
[34] conjugates than p-isothiocyanotobenzyl linker. Because 
of its reactivity, it can be used for labeling of other amino 
acid residues besides lysine and even labeling of sugars. The 
high reactivity can also be a disadvantage. A number of 
monoclonal antibodies lose easily their affinity when con-
jugated with 4,6-dichloro-1,3,5-triazin-2-ylamino-activated 
chelate. 
In connection with the present invention, the 
p-isothiocyanotobenzyl group was selected for preparation 
15 -S-C6H 4-NH2 moieties will be derivatized by thiophos-
gene. The ratio between the two stabilizers can be adjusted 
so that 1-2 reactive p-isothiocyanato groups per nanopar-
ticle are produced. This will ensure a better control over the 
NP-protein conjugate and will minimize possible adverse 
20 effects on protein activity. 
To speed up the procedure of preparation of labeled 
compounds-an important requirement when working with 
short half-life radionuclides-one can use a 
p-isothiocyanato bearing thiol, HS-CH2-C6H 4-NCS 
25 from the beginning of the nanoparticle synthesis as a stabi-
lizer. This will produce labels suitable for conjugation to 
proteins within a 10-15 minutes after obtaining a radionu-
clide as compared to a typical chelating procedure which 
requires several hours to incorporate a metal ion into the 
30 macrocyclic cage. 
35 
Controlled ratio of different moieties coating NP can be 
achieved by variation of the ratio of stabilizers in the 
reaction mixture for NP preparation. Since each nanoparticle 
bears a substantial number of stabilizing groups (> 10) on its 
surface, the statistical distribution will reflect quite accu-
rately the concentrations of the corresponding molecules and 
their relative reactivity toward binding to a growing metal 
sulfide cluster. Detection of the number of reactive groups 
per nanoparticle can be achieved by spectroscopic tech-
40 niques. 
It is necessary to mention that, very fine degree of control 
over the number of reactive groups on the surface of 
nanoparticles is desirable but not a mandatory prerequisite 
45 
for the preparation of radioimmunoconjugates. Assuming 
quite a broad distribution of reactive groups per 
nanoparticle-the number of ----(CH2)n-C6H 4-NCS moi-
eties varies between 1 and 5. The product of coupling to a 
protein may contain both crosslinked products and unreacted 
50 
----(CH2)n-C6H4-NCS groups. The latter can be easily 
quenched by addition of a lysine or a low molecular weight 
amine. As to the crosslinked species, they can be readily 
separated by centrifugation. 
of the first examples of NP-protein conjugates due to sim-
plicity and mild and efficient coupling to proteins (FIG. 2). 55 
In perspective this method appears to be well suitable for the 
preparation of mAbs conjugates and radiopharmaceuticals. 
One can use two alternative routes to produce SCN-
C6Hc---derivatized metal sulfide nanoparticles. Both of 
them are quite universal in respect to the type of metal 60 
sulfide NPs being attached. The first protocol involves an 
intermediate activation step and offers variable degree of 
conjugation. In a series of preliminary experiments it was 
demonstrated that p-thioaniline (HS-C6H4-NH2) is effi-
cient stabilizer for PbS, ReS2 and In2S3 nanoparticles. Their 65 
surface derivatized with -S-C6H4-NH2 groups is a 
convenient precursor for generation of -C6H4-NCS. 
The activity of all proteins after conjugation can be 
established by ELISA, registering the kinetics of the color 
development (formation of purpurogallin from pyrogallol at 
pH=6.0 at 20° C.). The molecular weight of the conjugates 
may be estimated initially by silver stain SDS-PAGE and by 
mass spectroscopy with electrospray ionization ( other ion-
ization methods have proven to damage both nanoparticles 
and proteins). 
Stability of the conjugates can be assessed by incubation 
with transferrin and excess of albumin at 37° C. for several 
hours in dark (the nanoparticles are likely to be light 
sensitive). The pH of the solution may be varied between 8.0 
and 4.0 to cover most of the biologically relevant pH 
conditions. The products can be separated by affinity chro-
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matography and the fractions collected and analyzed by 
atomic ionization spectroscopy for the presence of the 
radiolabel. Incubation in human serum may also be used for 
more rigorous stability characterization. The extent of tran-
schelation can be evaluated by the amount of a ionized form 5 
of metal assessed spectroscopically and electrochemically 
after chromatographic separation of the fraction with nano-
particles. 
Any heterogeneous conjugates constructed can be frac-
tionated by chromatography and analyzed by ELISA, immu- 10 
nofluorescence and SDS-PAGE in order to establish the 
12 
speed and mild, efficient coupling to proteins. In perspective 
this method is well suited for the preparation of mAbs 
conjugates and radiopharmaceuticals. 
Similarly to proteins, a nanoparticle can accommodate 
several biotin moieties. These isomers can be easily sepa-
rated by affinity chromatography on modified Sepharose. 
The actual number of B-groups per metal sulfide cluster can 
be determined spectroscopically (NMR, MS) and by clas-
sical colorimetric method based on the displacement of the 
dye 4-hydroxyazobenzene-2-carboxylic acid (HABA) from 
the binding sites of avidin [39]. HABA binds to avidin to 
give an absorption maximum at 500 nm. When biotin or 
biotinylated species are added, biotin displaces HABAfrom 
avidin and the absorbency at 500 nm is reduced. The 
presence of two distinct biological moieties attached to one 
NP. An example of an advanced conjugate consisting of two 
different biological moieties can be constructed using biotin 
(vitamin H) and streptavidin (Mw=60,000). Numerous bioti-
nylated proteins are widely available commercially. Bioti-
nylated horseradish peroxidaze may be employed for easy 
detection in the corresponding constructs. F(ab=)2 fragment 
15 decrease in absorbency is then used to determine the extent 
of biotinylation. Preparation of NPs with 1,2,3,4 etc. biotin 
groups on the surface opens unique possibilities for molecu-
lar engineering of nanoparticles and creation of superstruc-
tures on their basis. of antibody to rabbit IgG including its FTIC-labeled analog 
may be used when antibody fragments rather than a whole 20 
antibody is desirable. Folic acid and small peptides such as 
somatostatin (Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-
Phe-Thr-Ser-Cys) with distinct affinity to cancer cells are to 
Long-chain derivatives, which can be produced by intro-
be considered as within the scope of this invention for 
conjugation to nanoparticles as well. 
A staggeringly large value of binding constant for non-
covalent interaction between biotin (B) and avidin or 
streptavidin (SA), logK=15, and four independent docking 
spots make biotin technology an important pathway to 
preparation of various conjugated systems. A large variety of 30 
biotinylated proteins, antibodies and peptides is commer-
cially produced. The biotin-streptavidin link renders the 
preparation of various conjugates simple and quite univer-
sal. 
ducing N-E-aminocaproic acid link between Band NHS, are 
somewhat preferential over a short connection obtained by 
condensation-NH2 and -NHS due to better steric position 
of the biotin group for subsequent docking to streptavidin. 
25 These conjugates are easier to hydrolyze and, therefore, are 
likely to compromise in-vivo stability of radioconjugates 
from Nps. 
Streptavidin derivative of NPs can be prepared following 
the procedure outlined above. Biotinylation of NPs can be 
accomplished by a number of ways via attachment to amine, 
aldehyde, carboxyl, thiol and phenol functional groups 
located on nanoparticle. For previously mentioned -S-
(CH2)n -NH2 stabilizer, N-hydroxysuccinimide (NHS) 
ester of biotin (B-NHS) can be a convenient conjugation 
agent (FIG. 3). A typical nanoparticle biotynilation proce-
dure can be the following. 
EXAMPLE 3 
Nanoparticles are dissolved in 0.1 M NaHCO3 aqueous 
solution at a concentration 2-5 mg/ml. An appropriate 
volume of 2-10 mg/ml solution of biotin-NHS is added to 
obtain biotin-NHS to nanoparticles ratios 0, 2, 5, 10, 20, and 
50. Each reaction mixture is allowed to stand for 2 hr at 
room temperature. The samples are extensively dialyzed 
against pure water. 
EXAMPLE 4 
Advanced conjugates are also within the scope of the 
present invention. Intact antibodies possess higher affinity to 
cancer but have long blood clearance time. Additionally, the 
whole mAbs are more immunogenic than their fragments. 
On the other hand F(ab=) and F(ab')2 having a lower 
molecular mass of 50 kDa and 100 kDa respectively, clear 
35 
the blood faster than mAb but demonstrate substantially 
worse T/B ratio. The hope for finding a solution to this 
dilemma has been recently offered in a series of works on 
chemically constructed assemblies of antibody fragments 
such as F(ab')2, F(ab'h, and F(ab')4 . Tumor uptake for these 
40 
assemblies was 2-2.5 times higher than for normal F(ab')2 
and similar to that observed with the intact mAb. For some 
of them accumulation in kidney or liver was greatly reduced. 
Thus, chemically engineered immunopharmaceuticals are 
envisioned to be a viable alternative to whole mAbs. 
45 Small peptides (somatostatin and its analogs), folic acid, 
bleomycin and other low molecular weight compounds with 
distinct tendency to accumulate in cancer cells should also 
be considered within the scope of this invention for creation 
of similar radiolabeled constructs. Particularly preferred is 
50 the combination of two different target moieties on one 
radio label, for instance mAb+peptide or somatostatin+F( ab') 
2. Engaging diverse adsorption mechanisms will increase the 
overall tumor uptake and will improve the distribution of 
"hot" particles in the target since different tumor-seeking 
55 agents have different sites of preferential adsorption within 
For an example of NP-protein conjugates, reference is 
made to a simple conjugation reaction between NP stabilized 
with a thiol bearing -NH2 groups, bovine serum albumin 
(BSA) and glutaroaldehide (G). Carboxyl groups on both 
ends of G react with amino groups of both nanoparticles and 60 
BSA, thereby establishing a link between them made of 
strong covalent bonds. The reaction proceeds at room or 
slightly elevated temperature ( 45° C.) for one hour, which 
preserves the biological activity of the protein. Gel electro-
phoresis experiments of the conjugates revealed that virtu- 65 
ally all NPs are bound to the protein. This conjugation 
technique is particularly attractive due to its simplicity, 
cancer tissue. 
Nanoparticles with multiple bonding points appear to be 
well suited for preparation of "designer antibodies". Homo-
geneous assemblies such as F(ab')4 can be prepared via 
extensive activation of the nanoparticle surface followed by 
the conjugation to F(ab')2 fragments. After formation of the 
desired aggregates unreacted aromatic p-isothiocyanato 
groups can be quenched by lysine. Depending on the length 
of the stabilizer and diameter of NP, two or three F(ab')2 
units are likely to get attached. The actual number of 
antibody fragments per NP can be determined by TEM and 
by SDS-PAGE. 
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Heterogeneous constructs containing two different moi-
eties can be prepared by using NP-biotin derivatives 
described above. A nanoparticle containing both -NH2 
groups and at least one biotin moiety can be conjugated to 
14 
2. The bioconjugate of claim 1 wherein said at least one 
biological vector molecule is selected from a group consist-
ing of monoclonal antibodies (mAb), fragments of mono-
clonal antibodies, and peptides. 
a monoclonal antibody or a small peptide via regular tech- 5 
niques by using -NH2 activation leaving the biotin group 
intact. The second part, for example, mAb, F(ab') will be 
appended via streptavidin linker. This method is likely to 
produce isomers due to multiple docking sites on streptavi-
din. However they can be readily separated due to large 10 
difference in molecular weight and size by using size exclu-
sion chromatography. 
3. The bioconjugate of claim 1 wherein the nanoparticle 
is a metal sulfide selected from a group consisting of Ag2S, 
PbS, CdS, In2S, CuS, Bi2 S3 and ReS2 . 
4. The bioconjugate of claim 1 wherein the nanoparticle 
is titanium oxide. 
5. The bioconjugate of claim 1, wherein the nanoparticle 
is surface stabilized by a molecule or molecules having a 
thiol functional group. 
As thus described there is provided exceptionally stable 
metal sulfide nanoparticles for replacing metal chelates in 
radioimmunoconjugates. Virtual elimination of ionic radio-
active species will improve the performance of radiolabeled 
compounds and decrease radiation damage to healthy tissue. 
As well, radioactive nanoparticles will simplify the prepa-
ration procedure, decrease the cost, and open new possibili-
ties for the creation of molecularly designed immunochemi-
cals. 
While the invention has been described with a certain 
degree of particularity, it is understood that the invention is 
not limited to the embodiment(s) set for herein for purposes 
of exemplification, but is to be limited only by the scope of 
the attached claim or claims, including the full range of 
equivalency to which each element thereof is entitled. 
What is claimed is: 
6. The bioconjugate of claim 5 wherein the thiol func-
tional group is selected from a group consisting of 
15 thioglycerol, mercaptosuccinic acid, thioglycolic acid, and 
l-amino-2-methyl-2-propanethiol. 
7. The bioconjugate of claim 1 wherein the nanoparticle 
is surface stabilized by a protein. 
8. The bioconjugate of claim 1 wherein the nanoparticle 
20 has a diameter between approximately 1 and 10 nm. 
9. The bioconjugate of claim 8 wherein the diameter of the 
nanoparticle is between 2 and 5 nm. 
10. The bioconjugate of claim 1 further comprising: a 
second biological moiety wherein said second biological 
25 moiety is different from said biological vector molecule. 
11. The bioconjugate of claim 10 wherein the second 
biological moiety is selected from a group consisting of 
biotinylated proteins, antibody fragments, folic acid, and 
somatostatin. 1. A bioconjugate, comprising: a radioactive, metal sulfide 
or metal oxide nanoparticle covalently linked to at least one 30 
biological vector molecule. * * * * * 
